AbbVie Inc. (NYSE:ABBV) Shares Sold by NTV Asset Management LLC

NTV Asset Management LLC reduced its position in AbbVie Inc. (NYSE:ABBV) by 12.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 37,823 shares of the company’s stock after selling 5,219 shares during the quarter. AbbVie comprises about 1.0% of NTV Asset Management LLC’s holdings, making the stock its 25th largest position. NTV Asset Management LLC’s holdings in AbbVie were worth $5,861,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ABBV. Connecticut Wealth Management LLC boosted its stake in shares of AbbVie by 14.1% in the fourth quarter. Connecticut Wealth Management LLC now owns 2,013 shares of the company’s stock valued at $312,000 after buying an additional 248 shares in the last quarter. Avidian Wealth Solutions LLC boosted its position in shares of AbbVie by 4.1% during the 4th quarter. Avidian Wealth Solutions LLC now owns 14,357 shares of the company’s stock worth $2,225,000 after purchasing an additional 564 shares in the last quarter. Avalon Trust Co grew its stake in shares of AbbVie by 8.9% during the 4th quarter. Avalon Trust Co now owns 4,050 shares of the company’s stock worth $628,000 after purchasing an additional 330 shares during the period. TCG Advisory Services LLC increased its holdings in shares of AbbVie by 38.5% in the 4th quarter. TCG Advisory Services LLC now owns 58,648 shares of the company’s stock valued at $9,089,000 after purchasing an additional 16,293 shares in the last quarter. Finally, AJOVista LLC acquired a new stake in shares of AbbVie in the fourth quarter valued at about $250,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV traded up $2.98 during midday trading on Friday, reaching $163.79. 5,850,102 shares of the company traded hands, compared to its average volume of 5,457,836. AbbVie Inc. has a twelve month low of $130.96 and a twelve month high of $182.89. The company has a debt-to-equity ratio of 5.02, a current ratio of 0.87 and a quick ratio of 0.76. The company has a fifty day moving average price of $173.42 and a 200 day moving average price of $161.10. The firm has a market capitalization of $290.01 billion, a price-to-earnings ratio of 48.60, a price-to-earnings-growth ratio of 2.03 and a beta of 0.61.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, April 26th. The company reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.26 by $0.05. The company had revenue of $12.31 billion for the quarter, compared to analyst estimates of $11.93 billion. AbbVie had a return on equity of 165.18% and a net margin of 11.02%. The company’s quarterly revenue was up .7% compared to the same quarter last year. During the same period last year, the company earned $2.46 earnings per share. On average, analysts expect that AbbVie Inc. will post 11.29 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be given a dividend of $1.55 per share. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.79%. The ex-dividend date is Friday, April 12th. AbbVie’s dividend payout ratio (DPR) is presently 183.98%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ABBV shares. BMO Capital Markets dropped their target price on shares of AbbVie from $195.00 to $180.00 and set an “outperform” rating for the company in a report on Monday, April 29th. Guggenheim boosted their price objective on shares of AbbVie from $188.00 to $190.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Truist Financial raised their target price on shares of AbbVie from $180.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 6th. William Blair raised shares of AbbVie from a “market perform” rating to an “outperform” rating in a research note on Monday, January 29th. Finally, Barclays lowered their price objective on shares of AbbVie from $195.00 to $187.00 and set an “overweight” rating for the company in a research note on Monday, April 29th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $174.31.

Insider Activity at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 21,082 shares of AbbVie stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $176.30, for a total transaction of $3,716,756.60. Following the transaction, the executive vice president now directly owns 55,903 shares in the company, valued at approximately $9,855,698.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Richard A. Gonzalez sold 138,616 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $177.27, for a total transaction of $24,572,458.32. Following the transaction, the chief executive officer now directly owns 519,099 shares in the company, valued at approximately $92,020,679.73. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Nicholas Donoghoe sold 21,082 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $176.30, for a total transaction of $3,716,756.60. Following the completion of the transaction, the executive vice president now directly owns 55,903 shares in the company, valued at $9,855,698.90. The disclosure for this sale can be found here. Insiders sold 383,324 shares of company stock worth $67,780,003 in the last quarter. 0.25% of the stock is owned by company insiders.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.